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“black box” warning label. 
The pendulum began to swing back in 
favor of aspirin, however, when Rothwell, a 
neurologist, noticed that fewer overall can-
cers had occurred among patients in the 
treatment arm of randomized trials launched 
in the 1980s to test aspirin as a way to pre-
vent stroke. Amassing details on the can-
cers from patients’ paper health records and 
U.K. health databases, his team initially con-
ﬁ rmed aspirin’s ability to ward off colorec-
tal cancers, reporting in 2007 that there were 
24% fewer cases and 35% fewer deaths in 
the aspirin group after several years. Then 
in late 2010, they reported that patients 
taking aspirin at any dose daily for at least 
5 years cut by 21% the long-term risk of 
dying from colorectal, gastrointestinal, 
esophageal, stomach, pancreatic, brain, 
lung, and prostate cancers.
Rothwell’s group expanded on these 
results in three papers published in The 
Lancet and The Lancet Oncology this 
spring. One, a meta-analysis of 51 random-
ized trials in which aspirin was taken daily, 
found 37% fewer deaths from cancers after 
5 years. (The study came 
with a large caveat: It 
excluded WHS and an ear-
lier trial that found no ben-
eﬁ t, the Physicians’ Health 
Study, because participants 
in each took aspirin only every other day.) 
This meta-analysis also found that while 
the aspirin group had more stomach bleeds, 
these incidents were not fatal—people 
recovered—and the bleeding risk went down 
after several years on aspirin. Another paper 
found that people on aspirin who developed 
cancer were 36% less likely to have tumors 
that had spread. A third paper found a 
“remarkable consistency” in the drop in can-
cers among aspirin users in epidemiologic 
studies and clinical trials, Rothwell says.
While these studies weren’t designed spe-
ciﬁ cally to test aspirin against cancer, some 
researchers say that because so many people 
now take aspirin off-label it would be difﬁ -
cult to conduct better tri-
als. The Rothwell studies 
are “probably the best evi-
dence we’ll ever have on this 
topic,” Chan says.
Weighing risks
Chan is part of an interna-
tional panel on cancer pre-
vention that, in response 
to the Rothwell studies, plans to update its 
stance on aspirin published 3 years ago. 
The group’s leader, epidemiologist Jack 
Cuzick of Queen Mary, University of Lon-
don expects the panel may suggest that 
people take low doses of aspirin daily start-
ing around age 50 and stopping by age 70, 
when the risk of internal bleeding rises. The 
group may also discuss whether doctors 
should screen patients for the ulcer-causing 
Helicobacter pylori bacterium, treating 
those who test positive with antibiotics 
before putting them on aspirin, to reduce 
the risk of bleeds. 
Some U.S. researchers also suggest that 
it’s time for the U.S. Preventive Services 
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Believer. Peter Rothwell’s can-
cer studies convinced him to 
take a daily aspirin.
HOW DOES TAKING ASPIRIN WARD OFF CANCER? RESEARCHERS 
still don’t understand the mechanism, a lack of knowledge that threat-
ens to frustrate development of better cancer prevention agents. 
But some say the latest clinical studies linking low-dose aspirin use 
with less cancer (see main story, p. 1471) suggest there’s no need to 
improve upon this 113-year-old workhorse drug.
Among its many known effects, aspirin, or acetylsalicylic acid, 
inhibits two forms of enzymes known as cyclooxygenases (COX) that 
convert arachidonic acid into lipids called prostaglandins. Prosta-
glandins made by COX-1 protect the stomach lining, while those made 
by COX-2 are involved in inﬂ ammation. Aspirin’s inhibitor effects 
on COX-1 seem to explain why the medicine can upset stom-
achs and trigger internal bleeding. Many researchers have 
concluded that aspirin prevents cancer mainly by blocking 
the activity of COX-2. That’s because the same inﬂ amma-
tion-driven responses that help tissue recovery from wound 
injury—cell division, blood vessel formation, and suppression 
of programmed cell death, for example—may also help tumors grow.
Several lines of evidence implicate COX-2 in cancer induction. 
The enzyme is overproduced in many cancer types; mice lacking 
its gene are less prone to colon cancer; and trials of nonsteroidal 
anti-inﬂ ammatory drugs (NSAIDs) that target only COX-2 protected 
against precancerous colon polyps in people at high risk. 
Reducing inﬂ ammation via COX-2 probably isn’t the only way aspi-
rin prevents cancer, however. “We are as a ﬁ eld getting down to some 
of the mechanisms, but it’s very complicated,” says Raymond Dubois 
of the MD Anderson Cancer Center in Houston, Texas. A decade ago, 
researchers found that aspirin can block production of a protein called 
NF-κB that protects cells from early death. Although the studies were 
done in the test tube at aspirin doses much higher than those in the 
bloodstream, the NF-κB hypothesis remains on the table—along with 
more than a dozen possible mechanisms—from inhibiting various cell 
growth pathways to targeting cancer stem cells. “There are a number 
of very different, divergent ideas,” says Asad Umar of the National Can-
cer Institute’s Division of Cancer Prevention in Bethesda, Maryland.
Some experts say new clinical studies of low-dose aspirin and can-
cer suggest that COX-2 isn’t directly involved at all. That’s because at 
low doses, the drug doesn’t block COX-2 but still impairs platelets, the 
small cell fragments in blood that help form clots, via the COX-1 path-
way. Studies suggest that platelets blunt the immune attack on cancer 
cells traveling in blood and produce growth factors that help them take 
root in a new place, notes University of Pennsylvania pharmacologist 
Garrett FitzGerald. Some experiments suggest that activated platelets 
can also stimulate the COX-2 pathway in adjacent cells, which would 
explain how aspirin, by damping COX-2 at the site of an injury, could 
block the early stages of colorectal cancer, says Carlo Patrono, a phar-
macologist at the Catholic University in Rome, Italy. 
Efforts to make an alternative to standard aspirin haven’t yet panned 
out. Several drugs that target only COX-2, notably Vioxx and Celebrex, 
unacceptably raised heart attack risk, for example. And a version of 
acetylsalicylic acid containing a chemical group called nitric oxide that 
was supposed to reduce side effects failed to gain regulatory approval. 
Some researchers are combining aspirin with other compounds such 
as a lipid to reduce stomach upset. But these are years from the clinic. 
For now, “I don’t think a better aspirin is the issue,” but rather ﬁ guring 
out which individuals stand to beneﬁ t from it most, FitzGerald says. –J.K. 
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